VolitionRX Ltd (VNRX) (Q3 2026) Earnings Call Highlights: Revenue Surges 157% as French ...
VolitionRX Ltd (VNRX) posted strong Q3 2026 revenue growth, slashed operating losses, and secured a major French government-funded sepsis study, though tight liquidity and uneven revenue remain Related Stocks: VNRX ,